Reply: OnabotulinumtoxinA should be considered in medication overuse withdrawal in patients with chronic migraine
- PMID: 31782777
- PMCID: PMC7261126
- DOI: 10.1093/brain/awz368
Reply: OnabotulinumtoxinA should be considered in medication overuse withdrawal in patients with chronic migraine
Erratum in
-
Erratum.Brain. 2020 Mar 1;143(3):e24. doi: 10.1093/brain/awaa007. Brain. 2020. PMID: 32333675 Free PMC article. No abstract available.
Comment on
-
Acute withdrawal and botulinum toxin A in chronic migraine with medication overuse: a double-blind randomized controlled trial.Brain. 2019 May 1;142(5):1203-1214. doi: 10.1093/brain/awz052. Brain. 2019. PMID: 30982843 Free PMC article. Clinical Trial.
-
OnabotulinumtoxinA should be considered in medication overuse withdrawal in patients with chronic migraine.Brain. 2020 Jan 1;143(1):e5. doi: 10.1093/brain/awz366. Brain. 2020. PMID: 31782764 No abstract available.
References
-
- Attal N, de Andrade DC, Adam F, Ranoux D, Teixeira MJ, Galhardoni R, et al.Safety and efficacy of repeated injections of botulinum toxin A in peripheral neuropathic pain (BOTNEP): A randomised, double-blind, placebo-controlled trial. Lancet Neurol 2016; 15: 555–65. - PubMed
-
- Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, et al.OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 2010; 30: 804–14. - PubMed
-
- Australian Government. Australian Public Assessment Report for Botulinum toxin Type A Proprietary Product Name: Botox [Internet]. 2011. Available from: https://www.tga.gov.au/sites/default/files/auspar-botox.pdf.
-
- Carlsen LN, Munksgaard SB, Jensen RH, Bendtsen L. Complete detoxification is the most effective treatment of medication-overuse headache: a randomized controlled open-label trial. Cephalalgia 2018; 38: 225–36. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
